CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Breast cancer

(2021) Sibylle Loibl et al.   LANCET

YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC

(2020) Yanwei Cui et al.   Cell Death & Disease

Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway

(2020) Zhiqiang Liu et al.   Molecular Therapy-Oncolytics

Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer

(2020) Yuxiang Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

(2019) Richard Gray et al.   LANCET

Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression

(2019) Jia Pei Lim et al.   CANCER LETTERS

Inhibition of Y box binding protein 1 suppresses cell growth and motility in colorectal cancer

(2019) Areumnuri Kim et al.   MOLECULAR CANCER THERAPEUTICS

YBX1 at the crossroads of non-coding transcriptome, exosomal, and cytoplasmic granular signaling

(2018) Padmanaban S. Suresh et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer

(2018) Tomohiro Shibata et al.   Oncotarget

High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma

(2017) Lei-lei Zhou et al.   EXPERIMENTAL CELL RESEARCH

Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

(2017) Carsten Denkert et al.   LANCET

Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients

(2016) Tina Gruosso et al.   EMBO Molecular Medicine

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma

(2016) Shilei Zhao et al.   OncoTargets and Therapy

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

(2015) George T. Budd et al.   JOURNAL OF CLINICAL ONCOLOGY

CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation

(2014) Emmanuel Martin et al.   NATURE

Y-box-binding protein 1 (YB-1) and its functions

(2012) I. A. Eliseeva et al.   BIOCHEMISTRY-MOSCOW

The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment

(2011) Monica Fornier et al.   Breast Journal

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer

(2011) Renaud Sabatier et al.   PLoS One

A gene expression signature identifies two prognostic subgroups of basal breast cancer

(2010) Renaud Sabatier et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA-binding specificity of Y-box protein 1

(2010) Jinjiang Dong et al.   RNA Biology